Hospital:

Wound Center Technology

Sechrist Hyperbaric Oxygen Therapy Chambers

Hyperbaric Oxygen Therapy (HBOT) is a clinical treatment where the patient breathes 100 percent oxygen intermittently while enclosed in a hyperbaric oxygen chamber at a pressure greater than one atmosphere. HBOT has been proven effective for many medical conditions. The Undersea and Hyperbaric Medicine Society has approved it to treat the following:

  • Enhancement of healing in selected problem wounds
  • Necrotizing soft tissue infections
  • Compromised skin grafts & flaps
  • Acute thermal burn injury

In addition, Medicare coverage determinations will reimburse in the U.S. for the following conditions:

  • Patient that has type I or type II diabetes and has a lower extremity wound due to diabetes
  • Patient that has a wound classified as Wagner grade III or higher 
  • Patient that has failed an adequate course of standard wound therapy

Hyperbaric medicine is effective for the above indications and many more because it enables five basic actions: hyper oxygenation of the body, the mechanical effects of increased pressure, the mass action of gasses, vasoconstriction and bacteriostasis.

Monoplace, or single-person, chambers are the most widely used for HBOT.​ Monoplace chambers are National Fire Protection Association (N.F.P.A.) Class B devices that can be pressurized up to 3 atmospheres absolute (ATA) with 100 percent oxygen.

For more information on chronic wound care technology or other wound care services available, please call 1-866-KHS-HEAL.

Negative-Pressure Wound Therapy with the V.A.C. Therapy System

Since its introduction in 1995 (U.S.) / 1994 (Europe), V.A.C.® Therapy has changed the way wounds are healed by Negative-Pressure Wound Therapy devices. With more published clinical evidence than any other form of NPWT, V.A.C. Therapy has been selected as the treatment of choice for more than 8 million wounds worldwide since 2014.
 
The integrated V.A.C. Therapy system promotes wound healing through NPWT. Delivering negative pressure at the wound site through a unique, proprietary dressing helps draw wound edges together, remove infectious materials and actively promote the formation of granulation tissue. These Mechanisms of Action (macrostrain, microstrain) lead to fast and effective wound healing and improved patient quality of life in a cost-effective way.

For more information on negative pressure technology or other wound care services available, please call 1-866-KHS-HEAL.

Organogenesis Skin Substitute Technology - Apligraf & Dermagraft

Apligraf®

Apligraf® is a living-cell-based product, developed by Organogenesis, and indicated for the treatment of venous leg ulcers and diabetic foot ulcers.

Apligraf® is:

  • The first bio-engineered cell based product to receive FDA approval (in 1998).
  • The only commercially available bi-layered, bio-engineered cell-based product.
  • The only product approved by the FDA to treat both diabetic foot ulcers and venous leg ulcers.

The two layers of Apligraf® make it effective in speeding up wound healing and achieving healing in wounds previously unresponsive to treatment.

Dermagraft

Adding Dermagraft helps to reestablish the dermal bed.

Chronic diabetic foot ulcers (DFUs) demonstrate impaired healing that results from multiple pathological factors (e.g. vascular insufficiency, altered cellular activity and a dysfunctional extracellular matrix), leading to a deficient wound bed, which often fails to respond to conventional therapy alone.

Dermagraft helps restore compromised DFU dermal bed and facilitates healing by providing a substrate over the patient’s own epithelial cells to help close the wound.

For more information on Organogenesis technology or other wound care services available, please call 1-866-KHS-HEAL.